MedTrace Logo

Pilot Medical Evaluation of the T50 Test

NCT03292029 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 776

Last updated 2022-02-09

No results posted yet for this study

Summary

This pilot study aims to evaluate in an exploratory way the predictive power of a novel in vitro test (T50 Calcification Inhibition Test, T50 CIT), which measures the mineralization inhibition capacity of blood, in terms of its association with time to all-cause mortality in haemodialysis patients.

Conditions

Interventions

DIAGNOSTIC_TEST

T50 Calcification Inhibition Test (CIT)

Measurement of predialysis T50 CIT and fetuin-A values in serum of hemodialysis patients

Sponsors & Collaborators

  • Fresenius Medical Care Deutschland GmbH

    lead INDUSTRY

Principal Investigators

  • Abraham Rincon Bello, Dr. · Fresenius Medical Care Spain

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-22
Primary Completion
2019-10-05
Completion
2020-03-04

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03292029 on ClinicalTrials.gov